Abstract
Cancers harboring dominant-negative p53 mutations are often aggressive and difficult to treat. Direct attempts to restore wild-type p53 function have produced little clinical benefit. We investigated whether targeting a p53-target gene could induce certain tumor-suppressor characteristics. We found that inhibition of stathmin, a microtubule regulator that can be transcriptionally repressed by wild-type p53, restored certain wild-type functions to cancer cells with mutant p53. Silencing of stathmin by small interfering RNA (siRNA) in mutant p53 cell lines lowered expression to that observed following activation of wild-type p53 by DNA damage in wild-type p53 cell lines. siRNA-induced repression of stathmin decreased cell proliferation, viability and clonogenicity in mutant p53 cell lines. Furthermore, knockdown of stathmin partially restored cell-cycle regulation and activation of apoptosis. Therefore, targeting stathmin, a gene product that is overexpressed in the presence of mutant p53, may represent a novel approach to treating cancers with aberrant p53 function.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Ahn J, Murphy M, Kratowicz S, Wang A, Levine AJ, George DL . (1999). Down-regulation of the stathmin/Op18 and FKBP25 genes following p53 induction. Oncogene 18: 5954–5958.
Alaiya AA, Franzen B, Fujioka K, Moberger B, Schedvins K, Silfversvard C et al. (1997). Phenotypic analysis of ovarian carcinoma: polypeptide expression in benign, borderline and malignant tumors. Int J Cancer 73: 678–683.
Alli E, Bash-Babula J, Yang JM, Hait WN . (2002). Effect of stathmin on the sensitivity to antimicrotubule drugs in human breast cancer. Cancer Res 62: 6864–6869.
Bieche I, Lachkar S, Becette V, Cifuentes-Diaz C, Sobel A, Lidereau R et al. (1998). Overexpression of the stathmin gene in a subset of human breast cancer. Br J Cancer 78: 701–709.
Bieche I, Manceau V, Curmi PA, Laurendeau I, Lachkar S, Leroy K et al. (2003). Quantitative RT–PCR reveals a ubiquitous but preferentially neural expression of the KIS gene in rat and human. Brain Res Mol Brain Res 114: 55–64.
Bossi G, Mazzaro G, Porrello A, Crescenzi M, Soddu S, Sacchi A . (2004). Wild-type p53 gene transfer is not detrimental to normal cells in vivo: implications for tumor gene therapy. Oncogene 23: 418–425.
Brattsand G . (2000). Correlation of oncoprotein 18/stathmin expression in human breast cancer with established prognostic factors. Br J Cancer 83: 311–318.
Bullock AN, Fersht AR . (2001). Rescuing the function of mutant p53. Nat Rev Cancer 1: 68–76.
Bykov VJ, Issaeva N, Shilov A, Hultcrantz M, Pugacheva E, Chumakov P et al. (2002). Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound. Nat Med 8: 282–288.
Castedo M, Perfettini JL, Roumier T, Andreau K, Medema R, Kroemer G . (2004). Cell death by mitotic catastrophe: a molecular definition. Oncogene 23: 2825–2837.
Chang CL, Hora N, Huberman N, Hinderer R, Kukuruga M, Hanash SM . (2001). Oncoprotein 18 levels and phosphorylation mediate megakaryocyte polyploidization in human erythroleukemia cells. Proteomics 1: 1415–1423.
Curmi PA, Nogues C, Lachkar S, Carelle N, Gonthier MP, Sobel A et al. (2000). Overexpression of stathmin in breast carcinomas points out to highly proliferative tumours. Br J Cancer 82: 142–150.
Faille A, De Cremoux P, Extra JM, Linares G, Espie M, Bourstyn E et al. (1994). p53 mutations and overexpression in locally advanced breast cancers. Br J Cancer 69: 1145–1150.
Fei P, El-Deiry WS . (2003). P53 and radiation responses. Oncogene 22: 5774–5783.
Foster BA, Coffey HA, Morin MJ, Rastinejad F . (1999). Pharmacological rescue of mutant p53 conformation and function. Science 286: 2507–2510.
Friedrich B, Gronberg H, Landstrom M, Gullberg M, Bergh A . (1995). Differentiation-stage specific expression of oncoprotein 18 in human and rat prostatic adenocarcinoma. Prostate 27: 102–109.
Fujiwara T, Cai DW, Georges RN, Mukhopadhyay T, Grimm EA, Roth JA . (1994). Therapeutic effect of a retroviral wild-type p53 expression vector in an orthotopic lung cancer model. J Natl Cancer Inst 86: 1458–1462.
Hanash SM, Strahler JR, Kuick R, Chu EH, Nichols D . (1988). Identification of a polypeptide associated with the malignant phenotype in acute leukemia. J Biol Chem 263: 12813–12815.
Harris SL, Levine AJ . (2005). The p53 pathway: positive and negative feedback loops. Oncogene 24: 2899–2908.
Haupt S, Berger M, Goldberg Z, Haupt Y . (2003). Apoptosis – the p53 network. J Cell Sci 116: 4077–4085.
Hollstein M, Sidransky D, Vogelstein B, Harris CC . (1991). p53 mutations in human cancers. Science 253: 49–53.
Hupp TR, Lane DP . (1994). Allosteric activation of latent p53 tetramers. Curr Biol 4: 865–875.
Johnsen JI, Aurelio ON, Kwaja Z, Jorgensen GE, Pellegata NS, Plattner R et al. (2000). p53-mediated negative regulation of stathmin/Op18 expression is associated with G(2)/M cell-cycle arrest. Int J Cancer 88: 685–691.
Levine AJ . (1997). p53, the cellular gatekeeper for growth and division. Cell 88: 323–331.
Livak KJ, Schmittgen TD . (2001). Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25: 402–408.
Margolis RL, Lohez OD, Andreassen PR . (2003). G1 tetraploidy checkpoint and the suppression of tumorigenesis. J Cell Biochem 88: 673–683.
Meek DW . (2000). The role of p53 in the response to mitotic spindle damage. Pathol Biol (Paris) 48: 246–254.
Murphy M, Ahn J, Walker KK, Hoffman WH, Evans RM, Levine AJ et al. (1999). Transcriptional repression by wild-type p53 utilizes histone deacetylases, mediated by interaction with mSin3a. Genes Dev 13: 2490–2501.
Oesterreich S, Fuqua SA . (1999). Tumor suppressor genes in breast cancer. Endocr Relat Cancer 6: 405–419.
Pietenpol JA, Stewart ZA . (2002). Cell cycle checkpoint signaling: cell cycle arrest versus apoptosis. Toxicology 181–182: 475–481.
Polager S, Ginsberg D . (2003). E2F mediates sustained G2 arrest and down-regulation of Stathmin and AIM-1 expression in response to genotoxic stress. J Biol Chem 278: 1443–1449.
Price DK, Ball JR, Bahrani-Mostafavi Z, Vachris JC, Kaufman JS, Naumann RW et al. (2000). The phosphoprotein Op18/stathmin is differentially expressed in ovarian cancer. Cancer Invest 18: 722–730.
Sionov RV, Haupt Y . (1999). The cellular response to p53: the decision between life and death. Oncogene 18: 6145–6157.
Sobel A, Tashjian Jr AH . (1983). Distinct patterns of cytoplasmic protein phosphorylation related to regulation of synthesis and release of prolactin by GH cells. J Biol Chem 258: 10312–10324.
Taylor WR, Agarwal ML, Agarwal A, Stacey DW, Stark GR . (1999). p53 inhibits entry into mitosis when DNA synthesis is blocked. Oncogene 18: 283–295.
Taylor WR, Stark GR . (2001). Regulation of the G2/M transition by p53. Oncogene 20: 1803–1815.
Thompson DA, Belinsky G, Chang TH, Jones DL, Schlegel R, Munger K . (1997). The human papillomavirus-16 E6 oncoprotein decreases the vigilance of mitotic checkpoints. Oncogene 15: 3025–3035.
Vecil GG, Lang FF . (2003). Clinical trials of adenoviruses in brain tumors: a review of Ad-p53 and oncolytic adenoviruses. J Neurooncol 65: 237–246.
Vogel C, Kienitz A, Hofmann I, Muller R, Bastians H . (2004). Crosstalk of the mitotic spindle assembly checkpoint with p53 to prevent polyploidy. Oncogene 23: 6845–6853.
Vogelstein B, Kinzler KW . (2004). Cancer genes and the pathways they control. Nat Med 10: 789–799.
Vogelstein B, Lane D, Levine AJ . (2000). Surfing the p53 network. Nature 408: 307–310.
Wallace-Brodeur RR, Lowe SW . (1999). Clinical implications of p53 mutations. Cell Mol Life Sci 55: 64–75.
Zhou J, Giannakakou P . (2005). Targeting microtubules for cancer chemotherapy. Curr Med Chem Anti-Canc Agents 5: 65–71.
Acknowledgements
This work was supported by US Public Health Service NCI CA 78695 and CA 72720.
Author information
Authors and Affiliations
Corresponding authors
Rights and permissions
About this article
Cite this article
Alli, E., Yang, JM. & Hait, W. Silencing of stathmin induces tumor-suppressor function in breast cancer cell lines harboring mutant p53. Oncogene 26, 1003–1012 (2007). https://doi.org/10.1038/sj.onc.1209864
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1209864
Keywords
This article is cited by
-
Knockdown of MRPL35 promotes cell apoptosis and inhibits cell proliferation in non-small-cell lung cancer
BMC Pulmonary Medicine (2023)
-
Mining the plasma-proteome associated genes in patients with gastro-esophageal cancers for biomarker discovery
Scientific Reports (2021)
-
Stathmin is overexpressed and regulated by mutant p53 in oral squamous cell carcinoma
Journal of Experimental & Clinical Cancer Research (2017)
-
Downregulation of stathmin 1 in human gallbladder carcinoma inhibits tumor growth in vitro and in vivo
Scientific Reports (2016)
-
Phase 1 Trial of Bi-shRNA STMN1 BIV in Refractory Cancer
Molecular Therapy (2015)